Tumor Biology

, Volume 31, Issue 5, pp 495–502 | Cite as

Synthesis and structural characterization of the peptide epitope of the ovarian cancer biomarker CA125 (MUC16)

  • Zach T. Berman
  • Lee J. Moore
  • Kathleen E. Knudson
  • Rebecca J. Whelan
Research Article

Abstract

A highly conserved region of 21 amino acids flanked by cysteine residues, contained within a larger repeated domain, has been proposed to be the antibody-binding site in the ovarian cancer biomarker CA125 (MUC16). In this study solid-phase peptide synthesis with Fmoc protection chemistry was used to assemble a 21-mer peptide corresponding to the most frequently occurring antibody binding sequence in CA125. Potentially significant sequence variants were also synthesized. Peptide secondary structure was investigated using Fourier transform infrared spectroscopy, revealing the consensus sequence peptide to be largely unstructured at physiological pH whether the cysteine residues were reduced or were oxidized to form an intramolecular disulfide bond. Substitution of serine for proline at position 8 (P8S) results in β-sheet formation in peptides involved in intramolecular disulfide bonds. This β-sheet structure does not persist in peptides incapable of intramolecular disulfide bonding because of sequence nor in peptides treated with the reducing agent dithiothreitol. In CA125, P8S is predicted to occur in ∼25% of repeat domains, suggesting that this structural motif is a non-negligible contributor to overall structure and function. These findings suggest that future structural characterization efforts of CA125 should be especially mindful of the amino acid sequence and oxidation state of the protein.

Keywords

CA125 MUC16 Ovarian cancer Biomarker Synthetic peptide Repeat domain Epitope Infrared spectroscopy FTIR 

References

  1. 1.
    American Cancer Society: All about ovarian cancer. http://www.cancer.org (2009).
  2. 2.
    Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68:1331–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Bast RC, Klug TL, St. John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Bast RC. Status of tumor markers in ovarian cancer screening. J Clin Oncol. 2003;21:200s–5s.CrossRefPubMedGoogle Scholar
  5. 5.
    Gupta D, Lis CG. Role of CA125 in predicting ovarian cancer survival—a review of the epidemiological literature. J Ovarian Res. 2009;2:13.CrossRefPubMedGoogle Scholar
  6. 6.
    Bast RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005;15 suppl 3:274–81.CrossRefPubMedGoogle Scholar
  7. 7.
    Zhang Z, Yu Y, Xu F, Berchuck A, van Haaften-Day C, Havrilesky LJ, et al. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol. 2007;107:526–31.CrossRefPubMedGoogle Scholar
  8. 8.
    O’Brien TJ, Beard JB, Underwood LJ, Dennis RA, Santin AD, York L. The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumor Biol. 2001;22:348–66.CrossRefGoogle Scholar
  9. 9.
    Yin BWT, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem. 2001;276:27371–5.CrossRefPubMedGoogle Scholar
  10. 10.
    O’Brien TJ, Beard JB, Underwood LJ, Shigemasa K. The CA 125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure. Tumor Biol. 2002;23:154–69.CrossRefGoogle Scholar
  11. 11.
    Yin BWT, Dnistrian A, Lloyd KO. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. Int J Cancer. 2002;98:737–40.CrossRefPubMedGoogle Scholar
  12. 12.
    Hattrup CL, Gendler SJ. Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol. 2008;70:431–57.CrossRefPubMedGoogle Scholar
  13. 13.
    Singh AP, Senapati S, Ponnusamy MP, Jain M, Lele SM, Davis JS, et al. Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. Lancet Oncol. 2008;9:1076–85.CrossRefPubMedGoogle Scholar
  14. 14.
    Imai S, Haga S, Kiyozuka Y. Epitope characterization of MUC1 antibodies. Tumor Biol. 1998;19 suppl 1:30–4.CrossRefGoogle Scholar
  15. 15.
    Schol DJ, Meulenbroek MFA, Snijdewint FGM, von Mensdorff-Pouilly S, Verstraeten RA, Murakami F, et al. “Epitope fingerprinting” using overlapping 20-mer peptides of the MUC1 tandem repeat sequence. Tumor Biol. 1998;19 suppl 1:35–45.CrossRefGoogle Scholar
  16. 16.
    Grinstead JS, Koganty RR, Krantz MJ, Longenecker BM, Campbell AP. Effect of glycosylation on MUC1 humoral immune recognition: NMR studies of MUC1 glycopeptide–antibody interactions. Biochem. 2002;41:9946–61.CrossRefGoogle Scholar
  17. 17.
    Fontenot JD, Tjandra N, Bu D, Ho C, Montelaro RC, Finn OJ. Biophysical characterization of one-, two-, and three-tandem repeats of human mucin (muc-1) protein core. Cancer Res. 1993;53:5386–94.PubMedGoogle Scholar
  18. 18.
    Ferreira CSM, Matthews CS, Missailidis S. DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUC1-binding single-stranded DNA aptamers. Tumor Biol. 2006;27:289–301.CrossRefGoogle Scholar
  19. 19.
    Warren DJ, Nustad K, Beard JB, O’Brien TJ. Expression and epitope characterization of a recombinant CA 125 repeat: fourth report from the ISOBM TD-1 workshop. Tumor Biol. 2009;30:51–60.CrossRefGoogle Scholar
  20. 20.
    Chan WC, White PD, editors. Fmoc solid phase peptide synthesis: a practical approach. New York: Oxford University Press; 2000.Google Scholar
  21. 21.
    Diem M. Introduction to modern vibrational spectroscopy. New York: John Wiley and Sons; 1993.Google Scholar
  22. 22.
    Barth A, Zscherp C. What vibrations tell us about proteins. Q Rev Biophys. 2002;35:369–430.CrossRefPubMedGoogle Scholar
  23. 23.
    Maeda T, Inoue M, Koshiba S, Yabuki T, Aoki M, Nunokawa E, et al. Solution structure of the SEA domain from the murine homologue of ovarian cancer antigen CA125 (MUC16). J Biol Chem. 2004;279:13174–82.CrossRefPubMedGoogle Scholar
  24. 24.
    Gubbels JAA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, et al. Mesothelin-MUC16 binding is a high-affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006;5:50.CrossRefPubMedGoogle Scholar
  25. 25.
    Kaneko O, Gong L, Zhang J, Hansen JK, Hassan R, Lee B, et al. A binding domain on mesothelein for CA125/MUC16. J Biol Chem. 2009;284:3739–49.CrossRefPubMedGoogle Scholar
  26. 26.
    Chen Y, Clark S, Wong T, Chen Y, Chen Y, Dennis MS, et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res. 2007;67:4924–32.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2010

Authors and Affiliations

  • Zach T. Berman
    • 1
  • Lee J. Moore
    • 1
  • Kathleen E. Knudson
    • 1
  • Rebecca J. Whelan
    • 1
  1. 1.Department of Chemistry and BiochemistryOberlin CollegeOberlinUSA

Personalised recommendations